The search for an effective coronavirus vaccine is widely noticed as one of the keys to helping the world become widespread again after the devastating effects of the pandemic.
The UK now has access to six other applicants for the covid-19 vaccine under development, in 4 other types, representing approximately 340 million doses, the Astra Zeneca-University of Oxford vaccine trial was briefly discontinued this month after a side effect was reported in a paciente. UK.
A week ago (12 September), he revealed that the trial would resume at all sites in the UK, as stated through the University of Oxford: “Ongoing randomized controlled clinical trials of the Oxford ChAdOx1 nCoV-19 coronavirus vaccine will fully resume clinical trial sites in the UK. “
Worldwide, another 18,000 people obtained the test vaccines as part of the trial.
The university stated that “in giant trials like this, some participants are expected to become ill and that each case will have to be thoroughly evaluated to ensure a full protection assessment. “
He added that the university may simply disclose medical data on the disease “for reasons of confidentiality of the participants. “
“We are committed to ensuring the protection of our participants and assembling the criteria of conduct in our studies and we will continue to strictly monitor protection,” the university added.
At a previous Downing Street briefing earlier this month, UK’s leading clinical adviser, Sir Patrick Vallance, said there is a “reasonable chance” that a vaccine will be obtained next year.
Receive the latest updates from all over Greater Manchester in your inbox with the MEN newsletter
You can log in by following the commands here
Sir Patrick said at a press conference on Downing Street that of the two hundred vaccine projects worldwide, six are in the “final phase of testing. “
He said many show the “right immune response. “
“This is a big step on the road to vaccine production,” Sir Patrick said at the briefing.
“I hope that by the end of the year we will have indications that some of them are working and have the right protection profile.
“I think there’s a moderate option that we can think about next year’s vaccination option at higher levels. “
Speaking in the Commons on Thursday (September 17) after pronouncing blockade measures in the Northeast, Matt Hancock asked when a vaccine will be launched.
He replied: “Of course, we will only allow a vaccine to be implemented to all grades when it is, and the MHRA (Medicines and Healthcare Products Regulatory Agency) is one of the most reputable and quality regulators in the world.
“They will take the decision on whether it is factoring a license – and of course, the consultation of who deserves to be vaccinated and in what order becomes a clinical resolution on which we will take the opinion of the joint vaccination commission. immunization. “
Priority teams such as frontline fitness workers, others with serious illnesses, the elderly, and BAME teams are the first to get a vaccine if a vaccine is approved.
Last month, Australia ordered 25 million doses of the Covid-19 vaccine developed through Oxford University in partnership with pharmaceutical company AstraZeneca, the country’s minister said.
In the UK, South Africa and Brazil, 3 large-scale trials are being conducted to verify its effectiveness in protecting against the virus.
Australian Prime Minister Scott Morrison promised to make the vaccine “as much as possible” in an interview with Melbourne radio station 3AW, before visiting AstraZeneca’s laboratory in Sydney.
He said at the time: “Today is a day of hope and Australia wants hope, the world wants hope, when it comes to this coronavirus. “
“And if we were able to do the tests, we hope it will be available early next year. If it can be done sooner, the better. “
In another radio interview, Morrison said he had recently spoken to French leader Emmanuel Macron about how the AstraZeneca vaccine is “one of the most productive customers in the world today. “
The UK government has received up to one hundred million doses of the AstraZeneca vaccine.
And the government announced earlier this month that it had reached agreements that it said would give British citizens 90 million doses of two other possible vaccines opposed to Covid-19.
Vaccines are developed through us biotechnology company Novavax and Belgium-based pharmaceutical company Janssen.
As a component of the agreements in principle, the UK has received 60 million doses of the Novavax vaccine, supporting a clinical trial with the National Institute of Health Research (NIHR).
Some 30 million doses of Janssen were received and ministers agreed in principle to co-finance a global clinic for their vaccine.
The non-profit Janssen vaccine is expected to begin the next phase of clinical trials later this year and read about whether two doses can provide long-term coverage against coronavirus.
Meanwhile, Novavax plans to manufacture its vaccine at Fujifilm Diosynth Biotechnologies facility in Billingham, Stockton-on-Tees in the Northeast once it becomes available.
The government has stated that if Novavax and Janssen vaccines are found to be a success in clinical trials, they may be sent to the UK until mid-2021.
Kate Bingham, chairwoman of the government’s vaccine working group, warned that it is not clear that any vaccines are effective.
She said: “The challenge is that we know which of these vaccines, if any, can work because there has been no vaccine that opposes a human coronavirus. “
“So what we’re doing is choosing six of the most promising vaccines from 4 other types of vaccines and we expect one of them to work.
“It would be a smart position if everyone works, but it’s not likely. The truth is that the maximum will fail and we must ensure that if one of them is effective and safe, we have the right to do so.
Ms. Bingham said she was “reasonably sure” that a vaccine would be discovered that would decrease the severity of coronavirus symptoms and decrease deaths.
And the Director General of the World Health Organization had a sobering message when he warned that there will never be a miracle cure for the coronavirus pandemic.
Dr. Tedros Adhanom Ghebreyesus said at a press conference: “Several vaccines are lately in phase 3 of clinical trials and we all hope to have a number of effective vaccines that can save you infection. “
He added: “However, there is no quick fix right now and there may never be. “
His comments are an assembly of the emergency committee of foreign experts convened through WHO.
The leading medical officer described this as a “moment of reflection” and noted that it happened six months after the coronavirus outbreak declared a public aptitude emergency of foreign interest.